SMA-560-luc Orthotopic Mouse Model Service for Brain Cancer

The SMA-560-luc orthotopic mouse model represents a spontaneously arising, immunocompetent glioma platform that authentically recapitulates the TGF-β-mediated immunosuppression and astrocytic differentiation of human anaplastic astrocytoma within the VM/Dk host. Alfa Cytology constructs, validates, and manages this luciferase-reporter syngeneic system with integrated bioluminescence tracking and neuropathological endpoints, delivering robust preclinical data to advance immunotherapy and targeted agent discovery programs.

Overview of SMA-560-luc Orthotopic Mouse Model for Brain Cancer

The SMA-560-luc orthotopic model is established by stereotactically implanting luciferase-transduced SMA-560 murine astrocytoma cells into the cerebrum of syngeneic VM/Dk mice, generating an intracranial tumor that closely mirrors the hyperchromatic nuclei, high cellularity, focal necrosis, and vascular proliferation characteristic of human anaplastic astrocytoma. Originally arising spontaneously in an inbred VM/Dk mouse rather than through chemical carcinogenesis, this transplantable astrocytoma retains robust expression of the differentiated astrocyte markers glial fibrillary acidic protein and glutamine synthetase while exhibiting low S-100 protein levels, supporting its faithful representation of astrocytic lineage tumors. The stable integration of firefly luciferase enables non-invasive, longitudinal bioluminescence imaging of tumor burden deep within the brain parenchyma, providing a quantitative readout for monitoring engraftment, expansion, and therapeutic response without serial magnetic resonance imaging or repeated terminal sampling.

Fig 1. Fractionated irradiation and/or TRAM-34 have little effect on blood counts in the SMA-560 VM/ Dk glioma model. (Stransky, Nicolai, et al., 2023)

A defining feature of the SMA-560 model is its constitutive expression of transforming growth factor-β, an immunosuppressive cytokine centrally implicated in glioblastoma pathogenesis through augmentation of tumor proliferation, invasion, angiogenesis, and immune evasion. The tumor cells display low baseline major histocompatibility complex class I expression and undetectable class II, alongside programmed death-ligand 1 positivity, creating a microenvironment that mimics the immune-suppressive milieu of human high-grade glioma. With a high mutational load yet moderate overall immunogenicity, the SMA-560-luc model occupies a unique niche for evaluating TGF-β inhibitors, dendritic cell vaccines, chimeric antigen receptor T-cell therapies, and antisense oligonucleotide strategies in a fully immunocompetent preclinical setting where innate and adaptive immune responses remain structurally intact.

Cell Line Information: SMA-560-luc

SMA-560-luc is a luciferase-reporter derivative of the SMA-560 murine astrocytoma cell line, generated through lentiviral transduction to stably express firefly luciferase for in vivo bioluminescent tracking. The parental SMA-560 line was originally derived from a spontaneous astrocytoma that arose in an inbred VM/Dk mouse and subsequently maintained by serial syngeneic transplantation before establishment as a permanent in vitro cell culture. Key attributes are summarized below:

Our Services

Our ServicesOur ServicesAlfa Cytology delivers comprehensive SMA-560-luc orthotopic glioma model services encompassing stereotactic surgical implantation, longitudinal bioluminescence imaging, and detailed neuropathological endpoint analysis with GFAP, glutamine synthetase, and TGF-β immunohistochemistry. Every study is conducted within fully accredited vivarium facilities under IACUC oversight, ensuring scientific precision, ethical compliance, and complete data traceability from model construction through final report delivery.

Workflow of SMA-560-luc Orthotopic Mouse Model Construction

Construction of the SMA-560-luc orthotopic glioma model employs stereotactic intracranial injection to deliver tumor cells into the cerebrum of VM/Dk mice, ensuring reproducible engraftment, minimal surgical morbidity, and consistent tumor kinetics. The protocol integrates pre-operative analgesia, aseptic stereotactic surgery, controlled cell infusion in methylcellulose carrier, and longitudinal bioluminescence monitoring, as outlined below:

1. Cell Preparation and Batch Validation: SMA-560-luc cells are expanded under low-passage conditions (passage 3–8) in antibiotic-free MEM (Richter's modification) supplemented with 10% FBS to preserve astrocytic differentiation and tumorigenic potential. Viability is confirmed by trypan blue exclusion (>95% required), and luciferase expression is validated via in vitro bioluminescence assay to ensure uniform reporter signal intensity across the batch.
2. Animal Selection and Acclimation: Female VM/Dk mice (8–12 weeks old, 20–22 g) are selected to maintain syngeneic compatibility and preserve intact tumor–immune interactions. A one-week acclimation period is observed under specific-pathogen-free housing, with daily health monitoring and body weight recording to establish individual baseline parameters.
3. Pre-Operative Analgesia and Anesthesia: Mice receive pre-operative analgesia comprising buprenorphine (0.1 mg/kg) and carprofen (5 mg/kg) subcutaneously. General anesthesia is induced and maintained with isoflurane (3% induction, 1.5–2% maintenance) delivered via nose cone, with continuous respiration and body temperature monitoring throughout the procedure.
4. Surgical Site Preparation: The scalp is shaved and depilatory cream is applied to remove fur, followed by sterilization with iodine solution. The mouse is secured in a stereotaxic frame with ear bars and a bite bar, and a single midline incision is made to expose the skull surface and identify the bregma landmark.
5. Craniotomy and Dural Exposure: A small burr hole is drilled at the predetermined stereotactic coordinates (2 mm to the right of the coronal suture, 4 mm below the skull surface relative to bregma) using a high-speed microdrill under constant saline cooling. The dura mater is carefully pierced to expose the underlying parenchyma without causing cortical trauma or hemorrhage.
6. Tumor Cell Injection: A 250-µL Hamilton syringe fitted with a 25-gauge needle is positioned at the target coordinates. SMA-560-luc cells (1 × 10⁴) resuspended in 5 µL of 2.5% methylcellulose are delivered using a Hamilton injector over 2 minutes at a constant infusion rate. The methylcellulose carrier prevents cell settling and ensures uniform tumor seeding within the cerebral parenchyma.
7. Needle Retraction and Wound Closure: The needle is left in place for an additional 2 minutes to prevent retrograde flow along the injection tract, then withdrawn slowly over 1 minute to minimize cell tracking. The scalp incision is closed with surgical sutures or tissue adhesive, and the mouse is transferred to a heated recovery chamber.
8. Post-Operative Care and Monitoring: Mice receive carprofen-supplemented drinking water (33 µg/mL) for 72 hours post-surgery and are monitored twice daily for neurological deficits, body weight, and wound integrity. Animals are allowed to recover for a minimum of 3 days before initiation of any imaging or treatment protocol.
9. Bioluminescence Imaging and Tumor Monitoring: Starting at day 3–7 post-implantation, tumor establishment and growth are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin administration (150 mg/kg). Regions of interest are drawn over the cranial vault, and photon flux (photons/sec/cm²/sr) is quantified to generate longitudinal growth curves for each animal.
10. Endpoint Analysis and Neuropathology: At study termination, mice are humanely euthanized and brains are excised, weighed, and processed for formalin-fixed paraffin embedding. Coronal serial sections are stained with H&E for morphological assessment, and immunohistochemistry is performed for Ki67, GFAP, glutamine synthetase, CD31, Iba1, and TGF-β to confirm tumor origin, astrocytic differentiation, proliferative index, vascular density, microglial activation, and immunosuppressive cytokine expression.

Fig 2. SMA-560-luc Orthotopic Mouse Model construction workflow.

Case Study-SMA-560-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, the SMA-560-luc orthotopic model was utilized to evaluate the efficacy of a novel antisense oligonucleotide therapeutic targeting TGF-β signaling in high-grade glioma. Following stereotactic implantation and confirmation of engraftment by bioluminescence imaging within the first week, cohorts were randomized to receive either the investigational TGF-β inhibitor or vehicle control. Longitudinal BLI revealed distinct growth trajectories between treatment arms, with the active compound cohort demonstrating attenuated photon flux accumulation relative to controls. Terminal neuropathological analysis showed reduced intracranial tumor burden, diminished microvascular proliferation, and elevated immune cell infiltration in treated animals, alongside preserved peritumoral brain architecture in responders. These preclinical findings informed the compound's mechanism-of-action hypothesis and supported advancement toward subsequent pharmacology and toxicology studies.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your SMA-560-luc orthotopic glioma program provides access to a specialized, quality-driven preclinical infrastructure optimized for VM/Dk syngeneic tumor research and immunosuppressive microenvironment evaluation. Our distinguishing capabilities include:

• Specialized expertise in VM/Dk syngeneic glioma model development, with optimized stereotactic surgical protocols that achieve consistent cerebral engraftment and physiologically relevant tumor progression in immunocompetent hosts.
• Integrated bioluminescence and small-animal MRI imaging platforms enabling non-invasive, quantitative longitudinal tracking of intracranial tumor dynamics without introducing serial sacrifice artifacts into your dataset.
• Rigorous cell banking and authentication procedures, encompassing mycoplasma screening, luciferase expression validation, short tandem repeat profiling, and TGF-β secretion quantification to ensure model fidelity and batch-to-batch reproducibility.
• Adaptable study architectures supporting single-agent screening, combination radio-immunotherapy regimens, dendritic cell vaccine evaluation, CAR T-cell therapy assessment, and antisense oligonucleotide profiling tailored to your therapeutic modality.
• Comprehensive neuropathological endpoint capabilities including digital histopathology, immunohistochemistry for astrocytic and immune markers, multiplex immunofluorescence, TGF-β ELISA, and flow cytometry of tumor-infiltrating leukocytes.
• A dedicated scientific project management team providing transparent milestone reporting, timeline accountability, and direct consultation from protocol design through final data package delivery.

Contact Us

Whether your program targets glioma with a TGF-β antisense oligonucleotide, a dendritic cell vaccine approach, a CAR T-cell therapy, or a blood-brain barrier-penetrant small molecule, Alfa Cytology is positioned to accelerate your preclinical development with our SMA-560-luc orthotopic glioma expertise. Contact us today to discuss your study design, review our imaging and surgical capabilities, and receive a customized proposal aligned with your scientific objectives and timeline. Our neuro-oncology team looks forward to collaborating with you to generate the robust, translationally relevant data your pipeline demands.

For research use only. Not intended for any clinical use.